← back to search

Tony Reid

CytRx (United States) · US
Area of research
Genetics · Biotechnology
Research interest
Research interests include Virus-based gene therapy research, Cancer Research and Treatments, HIV/AIDS Research and Interventions, and Global Maternal and Child Health.
h-index
40
citations
6,447
works
182
NIH funding
primary concept
email

Recent publications

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors
Future Oncology 2022cited by 14position: middledoi
Locally advanced rectal cancer: The past, present, and future
Seminars in Oncology 2020cited by 105position: middledoi
Just eat it: A review of CD47 and SIRP-α antagonism
Seminars in Oncology 2020cited by 87position: middledoi
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Clinical Cancer Research 2019cited by 259position: middledoi
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
The Lancet Oncology 2015cited by 90position: firstdoi
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Nature Medicine 2013cited by 771position: middledoi
Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results
Journal of Clinical Oncology 2013cited by 182position: middledoi
Obstetric Fistula in Burundi: a comprehensive approach to managing women with this neglected disease
BMC Pregnancy and Childbirth 2013cited by 63position: middledoi
Does <scp>HIV</scp> status affect the aetiology, bacterial resistance patterns and recommended empiric antibiotic treatment in adult patients with bloodstream infection in Cambodia?
Tropical Medicine & International Health 2013cited by 17position: middledoi
Abstract LB-86: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent.
Cancer Research 2013cited by 1position: firstdoi
Is operational research delivering the goods? The journey to success in low-income countries
The Lancet Infectious Diseases 2012cited by 88position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2013–2022)Anthony Harries · London School of Hygiene & Tropical Medicine3 papers (2012–2013)Susan J. Knox · Palo Alto University3 papers (2015–2020)Meaghan Stirn · CytRx (United States)2 papers (2015–2022) · 2 papers (2012–2013)Howard A. Burris · Sarah Cannon2 papers (2013–2015)Rony Zachariah · World Health Organization2 papers (2012–2013)Jeffrey R. Infante · Janssen (United States)2 papers (2013–2015)Minhtran Ngo · Baylor College of Medicine1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2015–2015)Anne Moon · Geisinger Medical Center1 papers (2013–2013)Michelle M. Kim · Michigan United1 papers (2015–2015)Noelle K. LoConte · University of Wisconsin–Madison1 papers (2019–2019)Pedro Cabrales · University of San Diego1 papers (2015–2015)Lisle M. Nabell · University of Alabama at Birmingham1 papers (2022–2022)